[go: up one dir, main page]

WO2017168390A3 - Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells - Google Patents

Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells Download PDF

Info

Publication number
WO2017168390A3
WO2017168390A3 PCT/IB2017/051868 IB2017051868W WO2017168390A3 WO 2017168390 A3 WO2017168390 A3 WO 2017168390A3 IB 2017051868 W IB2017051868 W IB 2017051868W WO 2017168390 A3 WO2017168390 A3 WO 2017168390A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
dopamine
receptor
parkinson
attenuation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/051868
Other languages
French (fr)
Other versions
WO2017168390A2 (en
Inventor
Rodrigo PACHECO
Hugo GONZÁLEZ
Daniela ELGUETA
Francisco CONTRERAS
Valentina UGALDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUNDACION CIENCIA PARA LA VIDA
Original Assignee
FUNDACION CIENCIA PARA LA VIDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUNDACION CIENCIA PARA LA VIDA filed Critical FUNDACION CIENCIA PARA LA VIDA
Publication of WO2017168390A2 publication Critical patent/WO2017168390A2/en
Publication of WO2017168390A3 publication Critical patent/WO2017168390A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Method for preventing or treating neurodegenerative diseases, based in treating in vitro or ex vivo CD4+ T cells obtained from a subject, with a dopamine D3 (D3R) receptor inhibitor compound, and reincorporating the pre-treated CD4+ T cells to the subject, in an autologous transplant.
PCT/IB2017/051868 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells Ceased WO2017168390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL00753-2016 2016-03-31
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Publications (2)

Publication Number Publication Date
WO2017168390A2 WO2017168390A2 (en) 2017-10-05
WO2017168390A3 true WO2017168390A3 (en) 2017-11-16

Family

ID=59963679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051868 Ceased WO2017168390A2 (en) 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells

Country Status (2)

Country Link
CL (1) CL2016000753A1 (en)
WO (1) WO2017168390A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016474A1 (en) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Ibd therapy by inhibition of drd3 in regulatory t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163773A1 (en) * 2001-10-29 2005-07-28 Mia Levite Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity
US20060246042A1 (en) * 1998-11-16 2006-11-02 Alison Davies Cells, culture methods, and their use in autologous transplantation therapy
US20100068138A1 (en) * 2002-09-14 2010-03-18 Amy Newman Structurally rigid dopamine d3 receptor selective ligands and process for making them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246042A1 (en) * 1998-11-16 2006-11-02 Alison Davies Cells, culture methods, and their use in autologous transplantation therapy
US20050163773A1 (en) * 2001-10-29 2005-07-28 Mia Levite Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity
US20100068138A1 (en) * 2002-09-14 2010-03-18 Amy Newman Structurally rigid dopamine d3 receptor selective ligands and process for making them

Also Published As

Publication number Publication date
WO2017168390A2 (en) 2017-10-05
CL2016000753A1 (en) 2017-11-10

Similar Documents

Publication Publication Date Title
MX2023004152A (en) Agricultural compositions for improved crop productivity and enhanced phenotypes.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
HK1222205A1 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MX363118B (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators.
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2015183920A3 (en) Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
WO2012149484A3 (en) Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
WO2018200481A8 (en) Methods of making improved human intestinal organoid compositions via application of strain and human intestinal organoid compositions thereof
HK1248140A1 (en) Extracellular matrix compositions for the treatment of cancer or immunological diseases
EP4374925A3 (en) Polymorphic forms of rad1901-2hcl
MY193650A (en) Extracellular matrix compositions
MX2020010722A (en) Anti-cd40 antibodies for use in prevention of graft rejection.
WO2010135401A3 (en) Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
EP4223315A3 (en) Method for synthesis of reactive conjugate clusters
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
IL276706A (en) Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
MX2020011986A (en) Compositions comprising glucose and hemicellulose and their use.
MX2023010875A (en) Transgenic rainbow shark.
MX2018006221A (en) Composition and methods for reducing corn-on-corn yield penalty.
WO2017112422A8 (en) In situ treatment of seed in furrow
WO2014133728A3 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
MX2021007160A (en) An artificial plant seed and uses thereof.
WO2018140850A3 (en) T cells derived from umbilical cord blood

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17773423

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17773423

Country of ref document: EP

Kind code of ref document: A2